Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07197294 · ClinicalTrials.gov registry record · Phase 1
Personalized Antisense Oligonucleotide for a Single Participant With MAPK8IP3 Neurodevelopmental Disorder With or Without Variable Brain Abnormalities (NEDBA)
A Phase 1 study of Neurodevelopmental Disorder With or Without Variable Brain Abnormalities, sponsored by n-Lorem Foundation.
- Active
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
- 1
- Study location
NCT07197294 is a Phase 1 study of Neurodevelopmental Disorder With or Without Variable Brain Abnormalities that is active but no longer recruiting, run by n-Lorem Foundation. The registered enrollment target is 1 participants. The trial reports 1 study location across 1 state.
The verdict
NCT07197294, a Phase 1 study of Neurodevelopmental Disorder With or Without Variable Brain Abnormalities, is active but no longer recruiting, sponsored by n-Lorem Foundation.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
- 1
- Study location
Study Summary
This research project entails delivery of a personalized antisense oligonucleotide (ASO) drug designed for a single participant with Neurodevelopmental Disorder with or without Brain Abnormalities (NEDBA) due to a heterozygous pathogenic missense mutation in MAPK8IP3
Conditions Studied
Interventions
- DRUG nL-MAPK8-001
Study Locations (1)
New York
- Columbia University - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2025-02-24 |
| Est. Completion | 2027-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07197294
The ClinicalTrials.gov registry entry for NCT07197294 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is n-Lorem Foundation, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neurodevelopmental Disorder With or Without Variable Brain Abnormalities appearing as the primary indexed condition, and to 1 intervention - of which nL-MAPK8-001 is the first listed.
NCT07197294 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT07197294 about?
NCT07197294 is a clinical study titled "Personalized Antisense Oligonucleotide for a Single Participant With MAPK8IP3 Neurodevelopmental Disorder With or Without Variable Brain Abnormalities (NEDBA)". This research project entails delivery of a personalized antisense oligonucleotide (ASO) drug designed for a single participant with Neurodevelopmental Disorder with or without Brain Abnormalities (NEDBA) due to a heterozygous pathogenic missense mutation in MAPK8IP3
What is the current status of trial NCT07197294?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2025-02-24. Estimated completion is 2027-02.
What conditions does trial NCT07197294 study?
This clinical trial studies the following conditions: Neurodevelopmental Disorder With or Without Variable Brain Abnormalities.
What interventions are being tested in trial NCT07197294?
The interventions under investigation include: nL-MAPK8-001 (DRUG).
Who is sponsoring clinical trial NCT07197294?
This trial is sponsored by n-Lorem Foundation, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07197294 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.